Towards a European Network for Multiple Sclerosis Trials (ENMST)

Ludwig Kappos, C. Polman, A. J. Thompson, P. Duda, M. Clanet, G. Comi, H. P. Hartung, X. Montalban

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Quality standards for clinical studies in the field of multiple sclerosis (MS) have improved significantly, to the great benefit of patients. This development has been accompanied by soaring costs and ever increasing complexity, with industry-independent trials having become virtually impossible. We propose establishing a European network that would include expertise in all the relevant aspects of MS treatment trials. In a stepwise approach, all interested active centres across Europe should be recruited into the network, based on agreement upon common scientific standards and quality requirements. Three main goals are discussed: • to facilitate identification of potentially useful agents for MS treatment; • to establish protocols for the interaction between investigators and industry; and • to identify common standards and a core set of data to allow for comparisons of MS trials. Collaboration with existing international organizations and institutions, especially the Sylvia Lawry Centre for MS Research, as well as with similar initiatives in North America and other parts of the world is envisaged.

Original languageEnglish
Pages (from-to)627-629
Number of pages3
JournalMultiple Sclerosis Journal
Volume9
Issue number6
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Multiple Sclerosis
Industry
North America
Research Personnel
Organizations
Costs and Cost Analysis
Therapeutics
Research

Keywords

  • Clinical trials
  • Methods
  • Multiple sclerosis
  • Quality standards

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Kappos, L., Polman, C., Thompson, A. J., Duda, P., Clanet, M., Comi, G., ... Montalban, X. (2003). Towards a European Network for Multiple Sclerosis Trials (ENMST). Multiple Sclerosis Journal, 9(6), 627-629. https://doi.org/10.1191/1352458503ms962xx

Towards a European Network for Multiple Sclerosis Trials (ENMST). / Kappos, Ludwig; Polman, C.; Thompson, A. J.; Duda, P.; Clanet, M.; Comi, G.; Hartung, H. P.; Montalban, X.

In: Multiple Sclerosis Journal, Vol. 9, No. 6, 12.2003, p. 627-629.

Research output: Contribution to journalArticle

Kappos, L, Polman, C, Thompson, AJ, Duda, P, Clanet, M, Comi, G, Hartung, HP & Montalban, X 2003, 'Towards a European Network for Multiple Sclerosis Trials (ENMST)', Multiple Sclerosis Journal, vol. 9, no. 6, pp. 627-629. https://doi.org/10.1191/1352458503ms962xx
Kappos, Ludwig ; Polman, C. ; Thompson, A. J. ; Duda, P. ; Clanet, M. ; Comi, G. ; Hartung, H. P. ; Montalban, X. / Towards a European Network for Multiple Sclerosis Trials (ENMST). In: Multiple Sclerosis Journal. 2003 ; Vol. 9, No. 6. pp. 627-629.
@article{7e7f69e024a64fa993f2d8d9e9cb83f9,
title = "Towards a European Network for Multiple Sclerosis Trials (ENMST)",
abstract = "Quality standards for clinical studies in the field of multiple sclerosis (MS) have improved significantly, to the great benefit of patients. This development has been accompanied by soaring costs and ever increasing complexity, with industry-independent trials having become virtually impossible. We propose establishing a European network that would include expertise in all the relevant aspects of MS treatment trials. In a stepwise approach, all interested active centres across Europe should be recruited into the network, based on agreement upon common scientific standards and quality requirements. Three main goals are discussed: • to facilitate identification of potentially useful agents for MS treatment; • to establish protocols for the interaction between investigators and industry; and • to identify common standards and a core set of data to allow for comparisons of MS trials. Collaboration with existing international organizations and institutions, especially the Sylvia Lawry Centre for MS Research, as well as with similar initiatives in North America and other parts of the world is envisaged.",
keywords = "Clinical trials, Methods, Multiple sclerosis, Quality standards",
author = "Ludwig Kappos and C. Polman and Thompson, {A. J.} and P. Duda and M. Clanet and G. Comi and Hartung, {H. P.} and X. Montalban",
year = "2003",
month = "12",
doi = "10.1191/1352458503ms962xx",
language = "English",
volume = "9",
pages = "627--629",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Towards a European Network for Multiple Sclerosis Trials (ENMST)

AU - Kappos, Ludwig

AU - Polman, C.

AU - Thompson, A. J.

AU - Duda, P.

AU - Clanet, M.

AU - Comi, G.

AU - Hartung, H. P.

AU - Montalban, X.

PY - 2003/12

Y1 - 2003/12

N2 - Quality standards for clinical studies in the field of multiple sclerosis (MS) have improved significantly, to the great benefit of patients. This development has been accompanied by soaring costs and ever increasing complexity, with industry-independent trials having become virtually impossible. We propose establishing a European network that would include expertise in all the relevant aspects of MS treatment trials. In a stepwise approach, all interested active centres across Europe should be recruited into the network, based on agreement upon common scientific standards and quality requirements. Three main goals are discussed: • to facilitate identification of potentially useful agents for MS treatment; • to establish protocols for the interaction between investigators and industry; and • to identify common standards and a core set of data to allow for comparisons of MS trials. Collaboration with existing international organizations and institutions, especially the Sylvia Lawry Centre for MS Research, as well as with similar initiatives in North America and other parts of the world is envisaged.

AB - Quality standards for clinical studies in the field of multiple sclerosis (MS) have improved significantly, to the great benefit of patients. This development has been accompanied by soaring costs and ever increasing complexity, with industry-independent trials having become virtually impossible. We propose establishing a European network that would include expertise in all the relevant aspects of MS treatment trials. In a stepwise approach, all interested active centres across Europe should be recruited into the network, based on agreement upon common scientific standards and quality requirements. Three main goals are discussed: • to facilitate identification of potentially useful agents for MS treatment; • to establish protocols for the interaction between investigators and industry; and • to identify common standards and a core set of data to allow for comparisons of MS trials. Collaboration with existing international organizations and institutions, especially the Sylvia Lawry Centre for MS Research, as well as with similar initiatives in North America and other parts of the world is envisaged.

KW - Clinical trials

KW - Methods

KW - Multiple sclerosis

KW - Quality standards

UR - http://www.scopus.com/inward/record.url?scp=0344961114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344961114&partnerID=8YFLogxK

U2 - 10.1191/1352458503ms962xx

DO - 10.1191/1352458503ms962xx

M3 - Article

VL - 9

SP - 627

EP - 629

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 6

ER -